[1]
Malve, H. Exploring the ocean for new drug developments: Marine pharmacology. J. Pharm. Bioallied Sci., 2016, 8(2), 83.
[2]
Alice, O.D.; Elegbede, I.O. Impact and challenges of marine medicine to man and its environment. Poult. Fish Wildl. Sci, 2016, 4, 160.
[3]
Ruiz-Torres, V.; Encinar, J.A.; Herranz-López, M.; Pérez-Sánchez, A.; Galiano, V.; Barrajón-Catalán, E.; Micol, V. An updated review on marine anticancer compounds: the use of virtual screening for the discovery of small-molecule cancer drugs. Molecules, 2017, 22(7), 1037.
[4]
Khan, Z.; Khan, A.A.; Yadav, H.; Prasad, G.B.; Bisen, P.S. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell. Mol. Biol. Lett., 2017, 22(1), 8.
[5]
Bae, I.S.; Kim, C.H.; Kim, J.M.; Cheong, J.H.; Ryu, J.I.; Han, M.H. Correlation of survivin and B-cell lymphoma 2 expression with pathological malignancy and anti-apoptotic properties of glial cell tumors. Biomed. Rep., 1899, 6(4), 396-400.
[6]
Rocha, J.; Peixe, L.; Gomes, N.; Calado, R. Cnidarians as a source of new marine bioactive compounds-An overview of the last decade and future steps for bioprospecting. Mar. Drugs, 2011, 9(10), 1860-1886.
[7]
Rasul, A.; Khan, M.; Ali, M.; Li, J.; Li, X. Targeting apoptosis pathways in cancer with alantolactone and isoalantolactone. Sci. World J., 2013, 2013, 248532.
[8]
Sithranga, B.N.; Kathiresan, K. Anticancer drugs from marine flora: An overview. J. Oncol., 2010, 2010, 214186.
[9]
Liu, J.; Ma, L.; Wu, N.; Liu, G.; Zheng, L.; Lin, X. Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway. Mar. Drugs, 2014, 12(9), 5072-5088.
[10]
Uddin, J.; Ueda, K.; Siwu, E.R.; Kita, M.; Uemura, D. Cytotoxic labdane alkaloids from an ascidian Lissoclinum sp.: Isolation, structure elucidation, and structure-activity relationship. Bioorg. Med. Chem., 2006, 14(20), 6954-6961.
[11]
Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M.; Cortistatins, A. B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex. J. Am. Chem. Soc., 2006, 128(10), 3148-3149.
[12]
Bajwa, N.; Liao, C.; Nikolovska-Coleska, Z. Inhibitors of the anti-apoptotic Bcl-2 proteins: A patent review. Expert Opin. Ther. Pat., 2012, 22(1), 37-55.
[13]
Pyrko, P.; Soriano, N.; Kardosh, A.; Liu, Y.T.; Uddin, J.; Petasis, N.A.; Schönthal, A.H. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol. Cancer, 2006, 5(1), 19.
[14]
Gong, A.; Ge, N.; Yao, W.; Lu, L.; Liang, H. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. Cancer Chemother. Pharmacol., 2014, 74(3), 531-538.
[15]
Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23(1-3), 3-25.
[16]
Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19(14), 1639-1662.
[17]
Morris, G.M.; Goodsell, D.S.; Huey, R.; Olson, A.J. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Des., 1996, 10(4), 293-304.
[18]
Goodsell, D.S.; Olson, A.J. Automated docking of substrates to proteins by simulated annealing. Proteins, 1990, 8(3), 195-202.
[20]
Wang, Y.; Xiao, J.; Suzek, T. O.; Zhang, J.; Wang, J.; Bryant, S. H. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res., 2016. 37(suppl_2), W623-W633.
[21]
Hess, B.; Kutzner, C.; Van Der Spoel, D.; Lindahl, E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput., 2008, 4(3), 435-447.
[22]
SchuÈttelkopf, A.W.; Van Aalten, D.M. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D, 2004, 60(8), 1355-1363.
[23]
van Gunsteren, W.F.; Billeter, S.R.; Eising, A.A.; Hünenberger, P.H.; Krüger, P.K.H.C.; Mark, A.E.; Tironi, I.G. Biomolecular simulation: The GROMOS96 manual and user guide, 1996.
[24]
Berendsen, H.J.; Postma, J.P.; van Gunsteren, W.F.; Hermans, J. Interaction models forwater in relation to protein hydration. Intermol. Forces, 1981, 14, 331-342.
[25]
Hess, B.; Bekker, H.; Berendsen, H.J.; Fraaije, J.G. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem., 1997, 18(12), 1463-1472.
[26]
Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in large systems. J. Chem. Phys., 1993, 98(12), 10089-10092.
[27]
Bussi, G.; Donadio, D.; Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys., 2007, 126(1), 014101.
[28]
Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys., 1981, 52(12), 7182-7190.
[29]
Singh, S.; Gupta, A.K.; Verma, A. Molecular Properties and Bioactivity score of the Aloe vera antioxidant compounds-in order to lead finding. Res. J. Pharm. Biol. Chem. Sci., 2013, 4(2), 876-881.
[30]
Bonate, P.L.; Howard, D.R., Eds.; Pharmacokinetics in Drug Development: Regulatory and development paradigms; (Vol. 2). Springer Science & Business Media, 2005.
[31]
Simmons, T.L.; Andrianasolo, E.; McPhail, K.; Flatt, P.; Gerwick, W.H. Marine natural products as anticancer drugs. Mol. Cancer Ther., 2005, 4(2), 333-342.
[32]
Newman, D.J.; Cragg, G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod., 2004, 67(8), 1216-1238.
[33]
Sakoguchi-Okada, N.; Takahashi-Yanaga, F.; Fukada, K.; Shiraishi, F.; Taba, Y.; Miwa, Y.; Sasaguri, T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol., 2007, 73(9), 1318-1329.
[34]
Konc, J.; Lešnik, S.; Janežič, D. Modeling enzyme-ligand binding in drug discovery. J. Cheminform., 2015, 7, 48.
[35]
Konc, J.; Janežič, D. Binding site comparison for function prediction and pharmaceutical discovery. Curr. Opin. Struct. Biol., 2014, 25, 34-39.
[36]
Konc, J.; Miller, B.T.; Stular, T.; Lesnik, S.; Woodcock, H.L.; Brooks, B.R.; Janezic, D. ProBiS-CHARMMing: Web interface for prediction and optimization of ligands in protein binding sites. J. Chem. Inf. Model., 2015, 55, 2308-2314.
[37]
Kumar, R.; Sharma, A.; Tiwari, R.K. Can we predict blood brain barrier permeability of ligands using computational approaches? Interdiscip. Sci., 2013, 5(2), 95-101.
[38]
Ogrizek, M.; Turk, S.; Lešnik, S.; Sosič, I.; Hodošček, M.; Mirković, B.; Kos, J.; Janežič, D.; Gobec, S.; Konc, J. Molecular dynamics to enhance structure-based virtual screening on cathepsin B. J. Comput. Aided Mol. Des., 2015, 29(8), 707-712.
43
3
2